FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Virol / Restriction of equine infectious anemia virus by equine APOB...
Journal of virology2009; 83(15); 7547-7559; doi: 10.1128/JVI.00015-09

Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.

Abstract: The mammalian APOBEC3 (A3) proteins comprise a multigene family of cytidine deaminases that act as potent inhibitors of retroviruses and retrotransposons. The A3 locus on the chromosome 28 of the horse genome contains multiple A3 genes: two copies of A3Z1, five copies of A3Z2, and a single copy of A3Z3, indicating a complex evolution of multiple gene duplications. We have cloned and analyzed for expression the different equine A3 genes and examined as well the subcellular distribution of the corresponding proteins. Additionally, we have tested the functional antiretroviral activity of the equine and of several of the human and nonprimate A3 proteins against the Equine infectious anemia virus (EIAV), the Simian immunodeficiency virus (SIV), and the Adeno-associated virus type 2 (AAV-2). Hematopoietic cells of horses express at least five different A3s: A3Z1b, A3Z2a-Z2b, A3Z2c-Z2d, A3Z2e, and A3Z3, whereas circulating macrophages, the natural target of EIAV, express only part of the A3 repertoire. The five A3Z2 tandem copies arose after three consecutive, recent duplication events in the horse lineage, after the split between Equidae and Carnivora. The duplicated genes show different antiviral activities against different viruses: equine A3Z3 and A3Z2c-Z2d are potent inhibitors of EIAV while equine A3Z1b, A3Z2a-Z2b, A3Z2e showed only weak anti-EIAV activity. Equine A3Z1b and A3Z3 restricted AAV and all equine A3s, except A3Z1b, inhibited SIV. We hypothesize that the horse A3 genes are undergoing a process of subfunctionalization in their respective viral specificities, which might provide the evolutionary advantage for keeping five copies of the original gene.
Get Full Text
Publication Date: 2009-05-20 PubMed ID: 19458006PubMed Central: PMC2708611DOI: 10.1128/JVI.00015-09Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study investigates how certain proteins in the horse genome inhibit certain viruses including the equine infectious anemia virus (EIAV). It also investigates why horses have multiple copies of these antiviral proteins and how these influence their response to different viruses.

Study Overview

  • The researchers focused on a group of proteins known as mammalian APOBEC3 (A3), which are known to prevent infection by retroviruses and retrotransposons – a type of jumping gene that can move around the genome.
  • These proteins are found on chromosome 28 of the horse genome. There are multiple A3 genes present in this region, including two copies of A3Z1, five of A3Z2, and a single copy of A3Z3. This suggested a fascinating evolution of these genes with considerable duplications.

Analyzing Gene Expression and Functionality

  • The research team cloned various equine A3 genes and evaluated their expression and the subcellular location of the related proteins. They also tested these genes’ capabilities to inhibit particular viruses: EIAV, Simian immunodeficiency virus (SIV), and Adeno-associated virus type 2 (AAV-2).
  • The results showed that hematopoietic cells (blood cell producing cells) of horses expressed at least five A3s. Circulating macrophages, a type of white blood cell targeted by EIAV, only expressed part of the A3 repertoire.

Discovering Antiviral Activities and Evolution of A3 Genes

  • They discovered that the five A3Z2 gene copies came about after three consecutive duplications in the horse lineage, following the split between Equidae (horse family) and Carnivora (meat-eating animals).
  • The team noted that the duplicated genes exhibited different antiviral properties against different viruses. For instance, the equine A3Z3 and A3Z2c-Z2d effectively inhibited EIAV, but other A3 genes displayed only weak anti-EIAV activity.
  • The researchers proposed that horse A3 genes may be undergoing a process of subfunctionalization in which each gene adapts to counteract specific viruses. This might offer an evolutionary advantage in maintaining numerous copies of the original gene.

Cite This Article

APA
Zielonka J, Bravo IG, Marino D, Conrad E, Perković M, Battenberg M, Cichutek K, Münk C. (2009). Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J Virol, 83(15), 7547-7559. https://doi.org/10.1128/JVI.00015-09

Publication

Journal of virology
ISSN: 1098-5514
NlmUniqueID: 0113724
Country: United States
Language: English
Volume: 83
Issue: 15
Pages: 7547-7559

Researcher Affiliations

Zielonka, Jörg
  • Division of Medical Biotechnology, Paul Ehrlich Institut, Langen, Germany.
Bravo, Ignacio G
    Marino, Daniela
      Conrad, Elea
        Perković, Mario
          Battenberg, Marion
            Cichutek, Klaus
              Münk, Carsten

                MeSH Terms

                • APOBEC Deaminases
                • Animals
                • Cell Line
                • Cytidine Deaminase / genetics
                • Cytidine Deaminase / metabolism
                • Cytosine Deaminase / genetics
                • Cytosine Deaminase / metabolism
                • Equine Infectious Anemia / enzymology
                • Equine Infectious Anemia / virology
                • Gene Expression
                • HeLa Cells
                • Horses
                • Humans
                • Infectious Anemia Virus, Equine / genetics
                • Infectious Anemia Virus, Equine / physiology
                • Molecular Sequence Data
                • Multigene Family

                References

                This article includes 100 references
                1. Balaggan KS, Binley K, Esapa M, Iqball S, Askham Z, Kan O, Tschernutter M, Bainbridge JW, Naylor S, Ali RR. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors.. J Gene Med 2006 Mar;8(3):275-85.
                  pubmed: 16299834doi: 10.1002/jgm.845google scholar: lookup
                2. Benton MJ, Donoghue PC. Paleontological evidence to date the tree of life.. Mol Biol Evol 2007 Jan;24(1):26-53.
                  pubmed: 17047029doi: 10.1093/molbev/msl150google scholar: lookup
                3. Bininda-Emonds OR, Cardillo M, Jones KE, MacPhee RD, Beck RM, Grenyer R, Price SA, Vos RA, Gittleman JL, Purvis A. The delayed rise of present-day mammals.. Nature 2007 Mar 29;446(7135):507-12.
                  pubmed: 17392779doi: 10.1038/nature05634google scholar: lookup
                4. Bishop KN, Holmes RK, Malim MH. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.. J Virol 2006 Sep;80(17):8450-8.
                  pmc: PMC1563846pubmed: 16912295doi: 10.1128/jvi.00839-06google scholar: lookup
                5. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. Cytidine deamination of retroviral DNA by diverse APOBEC proteins.. Curr Biol 2004 Aug 10;14(15):1392-6.
                  pubmed: 15296758doi: 10.1016/j.cub.2004.06.057google scholar: lookup
                6. Bogerd HP, Tallmadge RL, Oaks JL, Carpenter S, Cullen BR. Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.. J Virol 2008 Dec;82(23):11889-901.
                  pmc: PMC2583693pubmed: 18818324doi: 10.1128/jvi.01537-08google scholar: lookup
                7. Bogerd HP, Wiegand HL, Doehle BP, Cullen BR. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains.. Virology 2007 Aug 1;364(2):486-93.
                  pmc: PMC1950718pubmed: 17434555doi: 10.1016/j.virol.2007.03.019google scholar: lookup
                8. Browne EP, Allers C, Landau NR. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent.. Virology 2009 May 10;387(2):313-21.
                  pmc: PMC3708462pubmed: 19304304doi: 10.1016/j.virol.2009.02.026google scholar: lookup
                9. Browne EP, Littman DR. Species-specific restriction of apobec3-mediated hypermutation.. J Virol 2008 Feb;82(3):1305-13.
                  pmc: PMC2224457pubmed: 18032489doi: 10.1128/jvi.01371-07google scholar: lookup
                10. Craigo JK, Durkin S, Sturgeon TJ, Tagmyer T, Cook SJ, Issel CJ, Montelaro RC. Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.. Vaccine 2007 Jan 15;25(5):834-45.
                  pmc: PMC1855206pubmed: 17023099doi: 10.1016/j.vaccine.2006.09.040google scholar: lookup
                11. Dang Y, Wang X, Esselman WJ, Zheng YH. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.. J Virol 2006 Nov;80(21):10522-33.
                  pmc: PMC1641744pubmed: 16920826doi: 10.1128/jvi.01123-06google scholar: lookup
                12. Derse D, Hill SA, Princler G, Lloyd P, Heidecker G. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.. Proc Natl Acad Sci U S A 2007 Feb 20;104(8):2915-20.
                  pmc: PMC1815281pubmed: 17299050doi: 10.1073/pnas.0609444104google scholar: lookup
                13. Doehle BP, Schäfer A, Wiegand HL, Bogerd HP, Cullen BR. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.. J Virol 2005 Jul;79(13):8201-7.
                  pmc: PMC1143768pubmed: 15956565doi: 10.1128/jvi.79.13.8201-8207.2005google scholar: lookup
                14. Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling trees.. BMC Evol Biol 2007 Nov 8;7:214.
                  pmc: PMC2247476pubmed: 17996036doi: 10.1186/1471-2148-7-214google scholar: lookup
                15. Edgar RC. MUSCLE: a multiple sequence alignment method with reduced time and space complexity.. BMC Bioinformatics 2004 Aug 19;5:113.
                  pmc: PMC517706pubmed: 15318951doi: 10.1186/1471-2105-5-113google scholar: lookup
                16. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput.. Nucleic Acids Res 2004;32(5):1792-7.
                  pmc: PMC390337pubmed: 15034147doi: 10.1093/nar/gkh340google scholar: lookup
                17. Elder JH, Lerner DL, Hasselkus-Light CS, Fontenot DJ, Hunter E, Luciw PA, Montelaro RC, Phillips TR. Distinct subsets of retroviruses encode dUTPase.. J Virol 1992 Mar;66(3):1791-4.
                  pmc: PMC240941pubmed: 1310783doi: 10.1128/jvi.66.3.1791-1794.1992google scholar: lookup
                18. Emi N, Friedmann T, Yee JK. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus.. J Virol 1991 Mar;65(3):1202-7.
                  pmc: PMC239887pubmed: 1847450doi: 10.1128/jvi.65.3.1202-1207.1991google scholar: lookup
                19. Fagerness AJ, Flaherty MT, Perry ST, Jia B, Payne SL, Fuller FJ. The S2 accessory gene of equine infectious anemia virus is essential for expression of disease in ponies.. Virology 2006 May 25;349(1):22-30.
                  pubmed: 16503341doi: 10.1016/j.virol.2005.12.041google scholar: lookup
                20. Fidalgo-Carvalho I, Craigo JK, Barnes S, Costa-Ramos C, Montelaro RC. Characterization of an equine macrophage cell line: application to studies of EIAV infection.. Vet Microbiol 2009 Apr 14;136(1-2):8-19.
                  pmc: PMC2689946pubmed: 19038510doi: 10.1016/j.vetmic.2008.10.010google scholar: lookup
                21. Force A, Lynch M, Pickett FB, Amores A, Yan YL, Postlethwait J. Preservation of duplicate genes by complementary, degenerative mutations.. Genetics 1999 Apr;151(4):1531-45.
                  pmc: PMC1460548pubmed: 10101175doi: 10.1093/genetics/151.4.1531google scholar: lookup
                22. Haché G, Liddament MT, Harris RS. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.. J Biol Chem 2005 Mar 25;280(12):10920-4.
                  pubmed: 15647250doi: 10.1074/jbc.m500382200google scholar: lookup
                23. Hakata Y, Landau NR. Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains.. J Biol Chem 2006 Dec 1;281(48):36624-31.
                  pubmed: 17020885doi: 10.1074/jbc.m604980200google scholar: lookup
                24. Harari A, Ooms M, Mulder LC, Simon V. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H.. J Virol 2009 Jan;83(1):295-303.
                  pmc: PMC2612324pubmed: 18945781doi: 10.1128/jvi.01665-08google scholar: lookup
                25. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. DNA deamination mediates innate immunity to retroviral infection.. Cell 2003 Jun 13;113(6):803-9.
                  pubmed: 12809610doi: 10.1016/s0092-8674(03)00423-9google scholar: lookup
                26. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.. Proc Natl Acad Sci U S A 2004 Jul 20;101(29):10774-9.
                  pmc: PMC490010pubmed: 15249685doi: 10.1073/pnas.0402361101google scholar: lookup
                27. Holmes RK, Koning FA, Bishop KN, Malim MH. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.. J Biol Chem 2007 Jan 26;282(4):2587-95.
                  pubmed: 17121840doi: 10.1074/jbc.m607298200google scholar: lookup
                28. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing?. Trends Biochem Sci 2007 Mar;32(3):118-28.
                  pubmed: 17303427doi: 10.1016/j.tibs.2007.01.004google scholar: lookup
                29. Hughes T, Liberles DA. The pattern of evolution of smaller-scale gene duplicates in mammalian genomes is more consistent with neo- than subfunctionalisation.. J Mol Evol 2007 Nov;65(5):574-88.
                  pubmed: 17957399doi: 10.1007/s00239-007-9041-9google scholar: lookup
                30. Iwatani Y, Chan DS, Wang F, Stewart-Maynard K, Sugiura W, Gronenborn AM, Rouzina I, Williams MC, Musier-Forsyth K, Levin JG. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G.. Nucleic Acids Res 2007;35(21):7096-108.
                  pmc: PMC2175344pubmed: 17942420doi: 10.1093/nar/gkm750google scholar: lookup
                31. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.. Genomics 2002 Mar;79(3):285-96.
                  pubmed: 11863358doi: 10.1006/geno.2002.6718google scholar: lookup
                32. Jern P, Stoye JP, Coffin JM. Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses.. PLoS Genet 2007 Oct;3(10):2014-22.
                  pmc: PMC2041998pubmed: 17967065doi: 10.1371/journal.pgen.0030183google scholar: lookup
                33. Jónsson SR, Haché G, Stenglein MD, Fahrenkrug SC, Andrésdóttir V, Harris RS. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins.. Nucleic Acids Res 2006;34(19):5683-94.
                  pmc: PMC1636497pubmed: 17038330doi: 10.1093/nar/gkl721google scholar: lookup
                34. Katzourakis A, Tristem M, Pybus OG, Gifford RJ. Discovery and analysis of the first endogenous lentivirus.. Proc Natl Acad Sci U S A 2007 Apr 10;104(15):6261-5.
                  pmc: PMC1851024pubmed: 17384150doi: 10.1073/pnas.0700471104google scholar: lookup
                35. Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, Uchiyama T. APOBEC3G targets specific virus species.. J Virol 2004 Aug;78(15):8238-44.
                  pmc: PMC446120pubmed: 15254195doi: 10.1128/jvi.78.15.8238-8244.2004google scholar: lookup
                36. Kummerfeld SK, Teichmann SA. Relative rates of gene fusion and fission in multi-domain proteins.. Trends Genet 2005 Jan;21(1):25-30.
                  pubmed: 15680510doi: 10.1016/j.tig.2004.11.007google scholar: lookup
                37. LaRue RS, Andrésdóttir V, Blanchard Y, Conticello SG, Derse D, Emerman M, Greene WC, Jónsson SR, Landau NR, Löchelt M, Malik HS, Malim MH, Münk C, O'Brien SJ, Pathak VK, Strebel K, Wain-Hobson S, Yu XF, Yuhki N, Harris RS. Guidelines for naming nonprimate APOBEC3 genes and proteins.. J Virol 2009 Jan;83(2):494-7.
                  pmc: PMC2612408pubmed: 18987154doi: 10.1128/jvi.01976-08google scholar: lookup
                38. LaRue RS, Jónsson SR, Silverstein KA, Lajoie M, Bertrand D, El-Mabrouk N, Hötzel I, Andrésdóttir V, Smith TP, Harris RS. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals.. BMC Mol Biol 2008 Nov 18;9:104.
                  pmc: PMC2612020pubmed: 19017397doi: 10.1186/1471-2199-9-104google scholar: lookup
                39. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein.. Science 2003 May 16;300(5622):1112.
                  pubmed: 12750511doi: 10.1126/science.1083338google scholar: lookup
                40. Leroux C, Cadoré JL, Montelaro RC. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?. Vet Res 2004 Jul-Aug;35(4):485-512.
                  pubmed: 15236678doi: 10.1051/vetres:2004020google scholar: lookup
                41. Leroux C, Craigo JK, Issel CJ, Montelaro RC. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.. J Virol 2001 May;75(10):4570-83.
                  pmc: PMC114210pubmed: 11312327doi: 10.1128/jvi.75.10.4570-4583.2001google scholar: lookup
                42. Li F, Leroux C, Craigo JK, Cook SJ, Issel CJ, Montelaro RC. The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies.. J Virol 2000 Jan;74(1):573-9.
                  pmc: PMC111574pubmed: 10590152doi: 10.1128/jvi.74.1.573-579.2000google scholar: lookup
                43. Li F, Puffer BA, Montelaro RC. The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro.. J Virol 1998 Oct;72(10):8344-8.
                  pmc: PMC110207pubmed: 9733881doi: 10.1128/jvi.72.10.8344-8348.1998google scholar: lookup
                44. Löchelt M, Romen F, Bastone P, Muckenfuss H, Kirchner N, Kim YB, Truyen U, Rösler U, Battenberg M, Saib A, Flory E, Cichutek K, Münk C. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein.. Proc Natl Acad Sci U S A 2005 May 31;102(22):7982-7.
                  pmc: PMC1142374pubmed: 15911774doi: 10.1073/pnas.0501445102google scholar: lookup
                45. Low A, Okeoma CM, Lovsin N, de las Heras M, Taylor TH, Peterlin BM, Ross SR, Fan H. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene.. Virology 2009 Mar 15;385(2):455-63.
                  pmc: PMC3124558pubmed: 19150103doi: 10.1016/j.virol.2008.11.051google scholar: lookup
                46. Luo K, Wang T, Liu B, Tian C, Xiao Z, Kappes J, Yu XF. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.. J Virol 2007 Jul;81(13):7238-48.
                  pmc: PMC1933265pubmed: 17428847doi: 10.1128/jvi.02584-06google scholar: lookup
                47. Lynch M, Force A. The probability of duplicate gene preservation by subfunctionalization.. Genetics 2000 Jan;154(1):459-73.
                  pmc: PMC1460895pubmed: 10629003doi: 10.1093/genetics/154.1.459google scholar: lookup
                48. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.. Nature 2003 Jul 3;424(6944):99-103.
                  pubmed: 12808466doi: 10.1038/nature01709google scholar: lookup
                49. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.. Cell 2003 Jul 11;114(1):21-31.
                  pubmed: 12859895doi: 10.1016/s0092-8674(03)00515-4google scholar: lookup
                50. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.. Nat Med 2003 Nov;9(11):1398-403.
                  pubmed: 14528301doi: 10.1038/nm946google scholar: lookup
                51. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y, Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus.. Gene Ther 1998 Jul;5(7):938-45.
                  pubmed: 9813665doi: 10.1038/sj.gt.3300680google scholar: lookup
                52. Maury W. Monocyte maturation controls expression of equine infectious anemia virus.. J Virol 1994 Oct;68(10):6270-9.
                  pmc: PMC237047pubmed: 8083967doi: 10.1128/jvi.68.10.6270-6279.1994google scholar: lookup
                53. Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, Olsen AL, Carter EE, Barber RD, Baban DF, Kingsman SM, Kingsman AJ, O'Malley K, Mitrophanous KA. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery.. Hum Mol Genet 2001 Sep 15;10(19):2109-21.
                  pubmed: 11590128doi: 10.1093/hmg/10.19.2109google scholar: lookup
                54. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, Brown WL, Mansky LM, Gorelick RJ, Harris RS, Engelman A, Pathak VK. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.. J Virol 2007 Jul;81(13):7099-110.
                  pmc: PMC1933301pubmed: 17428871doi: 10.1128/jvi.00272-07google scholar: lookup
                55. Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, Kim V, Kingsman S, Kingsman A, Mazarakis N. Stable gene transfer to the nervous system using a non-primate lentiviral vector.. Gene Ther 1999 Nov;6(11):1808-18.
                  pubmed: 10602376doi: 10.1038/sj.gt.3301023google scholar: lookup
                56. Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.. J Virol 2007 Dec;81(24):13346-53.
                  pmc: PMC2168852pubmed: 17928335doi: 10.1128/jvi.01361-07google scholar: lookup
                57. Muckenfuss H, Hamdorf M, Held U, Perković M, Löwer J, Cichutek K, Flory E, Schumann GG, Münk C. APOBEC3 proteins inhibit human LINE-1 retrotransposition.. J Biol Chem 2006 Aug 4;281(31):22161-22172.
                  pubmed: 16735504doi: 10.1074/jbc.m601716200google scholar: lookup
                58. Münk C, Beck T, Zielonka J, Hotz-Wagenblatt A, Chareza S, Battenberg M, Thielebein J, Cichutek K, Bravo IG, O'Brien SJ, Löchelt M, Yuhki N. Functions, structure, and read-through alternative splicing of feline APOBEC3 genes.. Genome Biol 2008;9(3):R48.
                  pmc: PMC2397500pubmed: 18315870doi: 10.1186/gb-2008-9-3-r48google scholar: lookup
                59. Münk C, Zielonka J, Constabel H, Kloke BP, Rengstl B, Battenberg M, Bonci F, Pistello M, Löchelt M, Cichutek K. Multiple restrictions of human immunodeficiency virus type 1 in feline cells.. J Virol 2007 Jul;81(13):7048-60.
                  pmc: PMC1933292pubmed: 17459941doi: 10.1128/jvi.02714-06google scholar: lookup
                60. Navarro F, Bollman B, Chen H, König R, Yu Q, Chiles K, Landau NR. Complementary function of the two catalytic domains of APOBEC3G.. Virology 2005 Mar 15;333(2):374-86.
                  pubmed: 15721369doi: 10.1016/j.virol.2005.01.011google scholar: lookup
                61. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.. Curr Biol 2005 Jan 26;15(2):166-70.
                  pubmed: 15668174doi: 10.1016/j.cub.2004.12.068google scholar: lookup
                62. OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution.. Cell Host Microbe 2008 Sep 11;4(3):249-59.
                  pmc: PMC2608726pubmed: 18779051doi: 10.1016/j.chom.2008.07.005google scholar: lookup
                63. OhAinle M, Kerns JA, Malik HS, Emerman M. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.. J Virol 2006 Apr;80(8):3853-62.
                  pmc: PMC1440450pubmed: 16571802doi: 10.1128/jvi.80.8.3853-3862.2006google scholar: lookup
                64. Okeoma CM, Lovsin N, Peterlin BM, Ross SR. APOBEC3 inhibits mouse mammary tumour virus replication in vivo.. Nature 2007 Feb 22;445(7130):927-30.
                  pubmed: 17259974doi: 10.1038/nature05540google scholar: lookup
                65. Okeoma CM, Low A, Bailis W, Fan HY, Peterlin BM, Ross SR. Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection.. J Virol 2009 Apr;83(8):3486-95.
                  pmc: PMC2663286pubmed: 19153238doi: 10.1128/jvi.02347-08google scholar: lookup
                66. Okeoma CM, Petersen J, Ross SR. Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection.. J Virol 2009 Apr;83(7):3029-38.
                  pmc: PMC2655539pubmed: 19153233doi: 10.1128/jvi.02536-08google scholar: lookup
                67. O'Rourke JP, Hiraragi H, Urban K, Patel M, Olsen JC, Bunnell BA. Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors.. Mol Ther 2003 May;7(5 Pt 1):632-9.
                  pubmed: 12718906doi: 10.1016/s1525-0016(03)00074-1google scholar: lookup
                68. Radcliffe PA, Sion CJ, Wilkes FJ, Custard EJ, Beard GL, Kingsman SM, Mitrophanous KA. Analysis of factor VIII mediated suppression of lentiviral vector titres.. Gene Ther 2008 Feb;15(4):289-97.
                  pubmed: 18046428doi: 10.1038/sj.gt.3303080google scholar: lookup
                69. Rohll JB, Mitrophanous KA, Martin-Rendon E, Ellard FM, Radcliffe PA, Mazarakis ND, Kingsman SM. Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors.. Methods Enzymol 2002;346:466-500.
                  pubmed: 11883086doi: 10.1016/s0076-6879(02)46072-7google scholar: lookup
                70. Ross SR. Are viruses inhibited by APOBEC3 molecules from their host species?. PLoS Pathog 2009 Apr;5(4):e1000347.
                  pmc: PMC2667636pubmed: 19390611doi: 10.1371/journal.ppat.1000347google scholar: lookup
                71. Russell RA, Wiegand HL, Moore MD, Schäfer A, McClure MO, Cullen BR. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.. J Virol 2005 Jul;79(14):8724-31.
                  pmc: PMC1168746pubmed: 15994766doi: 10.1128/jvi.79.14.8724-8731.2005google scholar: lookup
                72. Saenz DT, Teo W, Olsen JC, Poeschla EM. Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins.. J Virol 2005 Dec;79(24):15175-88.
                  pmc: PMC1316021pubmed: 16306589doi: 10.1128/jvi.79.24.15175-15188.2005google scholar: lookup
                73. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, Hasenkrug KJ, Greene WC. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection.. Science 2008 Sep 5;321(5894):1343-6.
                  pmc: PMC2701658pubmed: 18772436doi: 10.1126/science.1161121google scholar: lookup
                74. Schröfelbauer B, Chen D, Landau NR. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).. Proc Natl Acad Sci U S A 2004 Mar 16;101(11):3927-32.
                  pmc: PMC374346pubmed: 14978281doi: 10.1073/pnas.0307132101google scholar: lookup
                75. Schumacher AJ, Haché G, Macduff DA, Brown WL, Harris RS. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.. J Virol 2008 Mar;82(6):2652-60.
                  pmc: PMC2259018pubmed: 18184715doi: 10.1128/jvi.02391-07google scholar: lookup
                76. Sellon DC, Fuller FJ, McGuire TC. The immunopathogenesis of equine infectious anemia virus.. Virus Res 1994 May;32(2):111-38.
                  pmc: PMC7134051pubmed: 8067050doi: 10.1016/0168-1702(94)90038-8google scholar: lookup
                77. Sellon DC, Perry ST, Coggins L, Fuller FJ. Wild-type equine infectious anemia virus replicates in vivo predominantly in tissue macrophages, not in peripheral blood monocytes.. J Virol 1992 Oct;66(10):5906-13.
                  pmc: PMC241467pubmed: 1382143doi: 10.1128/jvi.66.10.5906-5913.1992google scholar: lookup
                78. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.. Nature 2002 Aug 8;418(6898):646-50.
                  pubmed: 12167863doi: 10.1038/nature00939google scholar: lookup
                79. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.. Nat Med 2003 Nov;9(11):1404-7.
                  pubmed: 14528300doi: 10.1038/nm945google scholar: lookup
                80. Shimodaira H, Hasegawa M. Multiple comparisons of log-likelihoods with applications to phylogenetic inference. Mol. Biol. Evol. 161114-1116.
                81. Sonnhammer EL, Koonin EV. Orthology, paralogy and proposed classification for paralog subtypes.. Trends Genet 2002 Dec;18(12):619-20.
                  pubmed: 12446146doi: 10.1016/s0168-9525(02)02793-2google scholar: lookup
                82. Sponseller BA, Sparks WO, Wannemuehler Y, Li Y, Antons AK, Oaks JL, Carpenter S. Immune selection of equine infectious anemia virus env variants during the long-term inapparent stage of disease.. Virology 2007 Jun 20;363(1):156-65.
                  pubmed: 17328936doi: 10.1016/j.virol.2007.01.037google scholar: lookup
                83. Stamatakis A. Phylogenetic models of rate heterogeneity: a high performance computing perspective. p. 278. In Proceedings of the 20th IEEE International Parallel and Distributed Processing Symposium, Rhodes, Greece. IEEE Computer Society, Washington, DC.
                84. Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models.. Bioinformatics 2006 Nov 1;22(21):2688-90.
                  pubmed: 16928733doi: 10.1093/bioinformatics/btl446google scholar: lookup
                85. Stamatakis A, Ludwig T, Meier H. RAxML-III: a fast program for maximum likelihood-based inference of large phylogenetic trees.. Bioinformatics 2005 Feb 15;21(4):456-63.
                  pubmed: 15608047doi: 10.1093/bioinformatics/bti191google scholar: lookup
                86. Suchard MA, Weiss RE, Sinsheimer JS. Bayesian selection of continuous-time Markov chain evolutionary models.. Mol Biol Evol 2001 Jun;18(6):1001-13.
                  pubmed: 11371589doi: 10.1093/oxfordjournals.molbev.a003872google scholar: lookup
                87. Suspène R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP. Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR.. J Gen Virol 2005 Jan;86(Pt 1):125-129.
                  pubmed: 15604439doi: 10.1099/vir.0.80426-0google scholar: lookup
                88. Suyama M, Torrents D, Bork P. PAL2NAL: robust conversion of protein sequence alignments into the corresponding codon alignments.. Nucleic Acids Res 2006 Jul 1;34(Web Server issue):W609-12.
                  pmc: PMC1538804pubmed: 16845082doi: 10.1093/nar/gkl315google scholar: lookup
                89. Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois MA, Neuberger MS, Rada C, Miyazawa M. Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo.. J Virol 2008 Nov;82(22):10998-1008.
                  pmc: PMC2573259pubmed: 18786991doi: 10.1128/jvi.01311-08google scholar: lookup
                90. Threadgill DS, Steagall WK, Flaherty MT, Fuller FJ, Perry ST, Rushlow KE, Le Grice SF, Payne SL. Characterization of equine infectious anemia virus dUTPase: growth properties of a dUTPase-deficient mutant.. J Virol 1993 May;67(5):2592-600.
                  pmc: PMC237580pubmed: 8386267doi: 10.1128/jvi.67.5.2592-2600.1993google scholar: lookup
                91. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.. EMBO J 2004 Jun 16;23(12):2451-8.
                  pmc: PMC423288pubmed: 15152192doi: 10.1038/sj.emboj.7600246google scholar: lookup
                92. Wolf D, Goff SP. Host restriction factors blocking retroviral replication.. Annu Rev Genet 2008;42:143-63.
                  pmc: PMC3598625pubmed: 18624631doi: 10.1146/annurev.genet.42.110807.091704google scholar: lookup
                93. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.. J Virol 1998 Mar;72(3):2224-32.
                  pmc: PMC109519pubmed: 9499080doi: 10.1128/jvi.72.3.2224-2232.1998google scholar: lookup
                94. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.. Science 2003 Nov 7;302(5647):1056-60.
                  pubmed: 14564014doi: 10.1126/science.1089591google scholar: lookup
                95. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.. Genes Dev 2004 Dec 1;18(23):2867-72.
                  pmc: PMC534647pubmed: 15574593doi: 10.1101/gad.1250204google scholar: lookup
                96. Zhang B, Jin S, Jin J, Li F, Montelaro RC. A tumor necrosis factor receptor family protein serves as a cellular receptor for the macrophage-tropic equine lentivirus.. Proc Natl Acad Sci U S A 2005 Jul 12;102(28):9918-23.
                  pmc: PMC1174982pubmed: 15985554doi: 10.1073/pnas.0501560102google scholar: lookup
                97. Zhang F, Hatziioannou T, Perez-Caballero D, Derse D, Bieniasz PD. Antiretroviral potential of human tripartite motif-5 and related proteins.. Virology 2006 Sep 30;353(2):396-409.
                  pubmed: 16828831doi: 10.1016/j.virol.2006.05.035google scholar: lookup
                98. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.. Nature 2003 Jul 3;424(6944):94-8.
                  pmc: PMC1350966pubmed: 12808465doi: 10.1038/nature01707google scholar: lookup
                99. Zhang W, Zhang X, Tian C, Wang T, Sarkis PT, Fang Y, Zheng S, Yu XF, Xu R. Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression.. Cell Microbiol 2008 Jan;10(1):112-21.
                  pubmed: 17672864doi: 10.1111/j.1462-5822.2007.01020.xgoogle scholar: lookup
                100. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.. J Virol 2004 Jun;78(11):6073-6.
                  pmc: PMC415831pubmed: 15141007doi: 10.1128/jvi.78.11.6073-6076.2004google scholar: lookup

                Citations

                This article has been cited 25 times.
                1. Wang XF, Zhang X, Ma W, Li J, Wang X. Host cell restriction factors of equine infectious anemia virus.. Virol Sin 2023 Aug;38(4):485-496.
                  doi: 10.1016/j.virs.2023.07.001pubmed: 37419416google scholar: lookup
                2. Shilova ON, Tsyba DL, Shilov ES. Mutagenic Activity of AID/APOBEC Deaminases in Antiviral Defense and Carcinogenesis.. Mol Biol 2022;56(1):46-58.
                  doi: 10.1134/S002689332201006Xpubmed: 35194245google scholar: lookup
                3. Christofi T, Zaravinos A. RNA editing in the forefront of epitranscriptomics and human health.. J Transl Med 2019 Sep 23;17(1):319.
                  doi: 10.1186/s12967-019-2071-4pubmed: 31547885google scholar: lookup
                4. de Pablo-Maiso L, Doménech A, Echeverría I, Gómez-Arrebola C, de Andrés D, Rosati S, Gómez-Lucia E, Reina R. Prospects in Innate Immune Responses as Potential Control Strategies against Non-Primate Lentiviruses.. Viruses 2018 Aug 17;10(8).
                  doi: 10.3390/v10080435pubmed: 30126090google scholar: lookup
                5. Milewska A, Kindler E, Vkovski P, Zeglen S, Ochman M, Thiel V, Rajfur Z, Pyrc K. APOBEC3-mediated restriction of RNA virus replication.. Sci Rep 2018 Apr 13;8(1):5960.
                  doi: 10.1038/s41598-018-24448-2pubmed: 29654310google scholar: lookup
                6. Ai Y, Ma J, Wang X. Clues for two-step virion infectivity factor regulation by core binding factor beta.. J Gen Virol 2017 May;98(5):1113-1121.
                  doi: 10.1099/jgv.0.000749pubmed: 28516844google scholar: lookup
                7. Nakano Y, Aso H, Soper A, Yamada E, Moriwaki M, Juarez-Fernandez G, Koyanagi Y, Sato K. A conflict of interest: the evolutionary arms race between mammalian APOBEC3 and lentiviral Vif.. Retrovirology 2017 May 8;14(1):31.
                  doi: 10.1186/s12977-017-0355-4pubmed: 28482907google scholar: lookup
                8. Zhang Z, Gu Q, Jaguva Vasudevan AA, Hain A, Kloke BP, Hasheminasab S, Mulnaes D, Sato K, Cichutek K, Häussinger D, Bravo IG, Smits SH, Gohlke H, Münk C. Determinants of FIV and HIV Vif sensitivity of feline APOBEC3 restriction factors.. Retrovirology 2016 Jul 1;13(1):46.
                  doi: 10.1186/s12977-016-0274-9pubmed: 27368163google scholar: lookup
                9. Nakaya Y, Stavrou S, Blouch K, Tattersall P, Ross SR. In Vivo Examination of Mouse APOBEC3- and Human APOBEC3A- and APOBEC3G-Mediated Restriction of Parvovirus and Herpesvirus Infection in Mouse Models.. J Virol 2016 Sep 1;90(17):8005-12.
                  doi: 10.1128/JVI.00973-16pubmed: 27356895google scholar: lookup
                10. Refsland EW, Hultquist JF, Luengas EM, Ikeda T, Shaban NM, Law EK, Brown WL, Reilly C, Emerman M, Harris RS. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.. PLoS Genet 2014 Nov;10(11):e1004761.
                  doi: 10.1371/journal.pgen.1004761pubmed: 25411794google scholar: lookup
                11. Yin X, Lin Y, Cai W, Wei P, Wang X. Comprehensive analysis of the overall codon usage patterns in equine infectious anemia virus.. Virol J 2013 Dec 20;10:356.
                  doi: 10.1186/1743-422X-10-356pubmed: 24359511google scholar: lookup
                12. Yin X, Hu Z, Gu Q, Wu X, Zheng YH, Wei P, Wang X. Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein.. J Virol 2014 Jan;88(2):1259-70.
                  doi: 10.1128/JVI.03148-13pubmed: 24227834google scholar: lookup
                13. Horn AV, Klawitter S, Held U, Berger A, Vasudevan AA, Bock A, Hofmann H, Hanschmann KM, Trösemeier JH, Flory E, Jabulowsky RA, Han JS, Löwer J, Löwer R, Münk C, Schumann GG. Human LINE-1 restriction by APOBEC3C is deaminase independent and mediated by an ORF1p interaction that affects LINE reverse transcriptase activity.. Nucleic Acids Res 2014 Jan;42(1):396-416.
                  doi: 10.1093/nar/gkt898pubmed: 24101588google scholar: lookup
                14. Stavrou S, Nitta T, Kotla S, Ha D, Nagashima K, Rein AR, Fan H, Ross SR. Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex.. Proc Natl Acad Sci U S A 2013 May 28;110(22):9078-83.
                  doi: 10.1073/pnas.1217399110pubmed: 23671100google scholar: lookup
                15. Münk C, Jensen BE, Zielonka J, Häussinger D, Kamp C. Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.. Viruses 2012 Nov 14;4(11):3132-61.
                  doi: 10.3390/v4113132pubmed: 23202519google scholar: lookup
                16. Münk C, Willemsen A, Bravo IG. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals.. BMC Evol Biol 2012 May 28;12:71.
                  doi: 10.1186/1471-2148-12-71pubmed: 22640020google scholar: lookup
                17. Denner J, Tönjes RR. Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses.. Clin Microbiol Rev 2012 Apr;25(2):318-43.
                  doi: 10.1128/CMR.05011-11pubmed: 22491774google scholar: lookup
                18. Smith HC, Bennett RP, Kizilyer A, McDougall WM, Prohaska KM. Functions and regulation of the APOBEC family of proteins.. Semin Cell Dev Biol 2012 May;23(3):258-68.
                  doi: 10.1016/j.semcdb.2011.10.004pubmed: 22001110google scholar: lookup
                19. Li MM, Emerman M. Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity.. J Virol 2011 Aug;85(16):8197-207.
                  doi: 10.1128/JVI.00624-11pubmed: 21653666google scholar: lookup
                20. Dörrschuck E, Fischer N, Bravo IG, Hanschmann KM, Kuiper H, Spötter A, Möller R, Cichutek K, Münk C, Tönjes RR. Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases.. J Virol 2011 Apr;85(8):3842-57.
                  doi: 10.1128/JVI.01880-10pubmed: 21307203google scholar: lookup
                21. Albin JS, Haché G, Hultquist JF, Brown WL, Harris RS. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.. J Virol 2010 Oct;84(19):10209-19.
                  doi: 10.1128/JVI.00632-10pubmed: 20686027google scholar: lookup
                22. Qi X, Wang X, Wang S, Lin Y, Jiang C, Ma J, Zhao L, Lv X, Shen R, Wang F, Kong X, Su Z, Zhou J. Genomic analysis of an effective lentiviral vaccine-attenuated equine infectious anemia virus vaccine EIAV FDDV13.. Virus Genes 2010 Aug;41(1):86-98.
                  doi: 10.1007/s11262-010-0491-6pubmed: 20526660google scholar: lookup
                23. Ooms M, Majdak S, Seibert CW, Harari A, Simon V. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.. J Virol 2010 Aug;84(16):7961-9.
                  doi: 10.1128/JVI.00754-10pubmed: 20519396google scholar: lookup
                24. Larue RS, Lengyel J, Jónsson SR, Andrésdóttir V, Harris RS. Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity.. J Virol 2010 Aug;84(16):8193-201.
                  doi: 10.1128/JVI.00685-10pubmed: 20519393google scholar: lookup
                25. Zielonka J, Marino D, Hofmann H, Yuhki N, Löchelt M, Münk C. Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids.. J Virol 2010 Jul;84(14):7312-24.
                  doi: 10.1128/JVI.00209-10pubmed: 20444897google scholar: lookup
                Subscribe to our newsletter
                Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.